AZD1043 Safety Study - AstraZeneca/Parexel
Summary
The National Library of Medicine updated ClinicalTrials.gov to add a new Phase 1 safety study for AZD1043 sponsored by AstraZeneca and Parexel. The trial is listed as 'not recruiting.' Clinical investigators and pharmaceutical sponsors should ensure their trials are properly registered.
What changed
ClinicalTrials.gov registered a new Phase 1 safety and tolerability study for investigational drug AZD1043. The trial is sponsored by AstraZeneca with Parexel as a site management organization and is currently listed as not recruiting. The registration includes standard trial metadata including study design, eligibility criteria, and anticipated endpoints.
Pharmaceutical sponsors conducting clinical trials subject to FDAAA 801 requirements should verify proper registration status and ensure any changes in recruitment status are updated on ClinicalTrials.gov within 30 days of a change. Clinical investigators should confirm their trial participation status aligns with current registry listings.
What to do next
- Verify trial registration compliance if subject to FDAAA 801
- Update recruitment status within 30 days of changes per FDAAA requirements
- Ensure all required registry fields are complete and accurate
Source document (simplified)
Show glossary
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.